References
- 1El-Hattab A, Adesina A, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015; 116(1–2): 4–12. DOI: 10.1016/j.ymgme.2015.06.004
- 2Bhatia K, Krishnan P, Kortman H, Klostranec J, Krings T. Acute cortical lesions in MELAS syndrome: Anatomic distribution, symmetry, and evolution. AJNR Am J Neuroradiol. 2019; 41(1): 167–173. DOI: 10.3174/ajnr.A6325
- 3Tetsuka S, Ogawa T, Hashimoto R, Kato H. Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS. Metab Brain Dis. 2021; 36(8): 2181–2193. DOI: 10.1007/s11011-021-00772-x
- 4Bensaidane M, Camden M, Savard M. Haemorrhagic Transformation of a MELAS stroke-like lesion. Can J Neurol Sci. 2019; 47(1): 117–118. DOI: 10.1017/cjn.2019.317
- 5Pénisson-Besnier I, Reynier P, Asfar P, et al. Recurrent brain hematomas in MELAS associated with an ND5 gene mitochondrial mutation. Neurology. 2000; 55(2): 317–318. DOI: 10.1212/WNL.55.2.317